Mandate

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.


The issuances were directed to new U.S. sector specialist investors. One of the issuances of warrants is subject to approval by an extraordinary general meeting.

Vinge’s team consisted of Dain Hård Nevonen, Lorin Arabi, Elias Kröger and Johannes Ekbom (Capital Markets and Public M&A).

Related

Vinge has advised Northmill Group AB in connection with the issuance of tier 2 capital bonds (T2)

Vinge has advised Northmill Group AB in connection with its successful issuance of SEK 150 million tier 2 capital bonds (T2) with a floating rate interest of 3-month STIBOR + 475 basis points.
September 11, 2026

Vinge advises IK Partners and Francks Kylindustri in connection with the acquisition of Helsingborgs Kylteknik

Vinge has advised IK Partners and its portfolio company Francks Kylindustri in connection with the acquisition of Helsingborgs Kylteknik, a company specialising in refrigeration technology and refrigeration services in southern Sweden. The acquisition strengthens Francks Kylindustri’s position in southern Sweden and broadens the group’s offering within the refrigeration industry.
September 11, 2026

Vinge advises the sellers of Berg Propulsion

Vinge has advised the sellers in connection with the sale of Berg Propulsion to Kongsberg Maritime.
September 10, 2026